Uptake at Your Biopsy or Surgery Site — on a PET Scan

If there is no procedure that explains uptake at a particular location, your team will evaluate it differently from post-procedure change. Uptake that cannot be attributed to a known biopsy, surgery, or other cause — such as physiological variation or recent infection — requires further assessment. This may include repeat imaging after an interval, or tissue sampling to establish whether the finding is a real lesion. Do not try to interpret the location or intensity yourself; ask your oncologist to walk through the report with you specifically.

EANM and ESMO guidance recommends allowing adequate time after a procedure before staging with FDG-PET, specifically to reduce the chance of post-procedure uptake being mistaken for disease. In practice, timing is sometimes constrained — an urgent clinical question may mean the scan cannot wait. Your oncologist weighed this when deciding when to scan. If the result is ambiguous because of a recent procedure, a follow-up scan at a better interval is a standard next step, not a failure of planning.

Yes. Port insertion, drain placement, bone marrow biopsy, pleurodesis, and any procedure that creates tissue disruption can produce the same inflammatory uptake. Radiologists routinely ask about recent procedures when reviewing PET-CT scans, and this information should be included on your referral. The more complete the procedural history provided by your team, the better placed the radiologist is to interpret any uptake at those sites correctly. If a procedure was not documented on the referral, it is worth raising with your oncologist.

Not on its own. Some inflammatory sites reach SUV values equal to or higher than cancer, and some low-grade malignancies show modest uptake. The number is one piece of data, not a verdict. The interpretation combines SUV with the CT appearance at the same site, the procedural history, the timing since the procedure, and — if available — comparison with previous scans. A high SUV in a healing area is not, by itself, evidence of cancer, and your oncologist should explain what the full interpretation shows.

'Indeterminate' means the radiologist cannot confidently explain the finding from this scan alone — and that conclusion is recorded honestly rather than guessed at. It usually comes with a recommendation: a follow-up scan after a defined interval, or tissue sampling at the site. An indeterminate report is not the same as a positive one. It is how uncertainty is managed safely and transparently. Ask your oncologist what the recommendation means in the context of your overall treatment plan and what you should watch for in the meantime.

This is a recognised limitation of FDG-PET, and radiologists are aware of it. Intense inflammatory uptake can reduce the conspicuity of a lesion immediately adjacent to the procedure site. If your team has a specific concern about a region near a biopsy or surgical site, it can be noted on the referral so the radiologist pays particular attention to that area. A follow-up scan once inflammation has settled, or cross-sectional imaging with MRI, may be planned if there is a clinical reason to look more carefully at a specific site.